

Chikungunya	Primary vaccination	Booster vaccination	Immunogenicity	Comments
<p>Vinkunya® (virus-like particle vaccine)</p> <p>Ixchiq® (live-attenuated vaccine)</p> <p>Dose: Vimkunya® : 0.8ml Ixchiq® : 0.5ml</p> <p>Application: i.m.</p> <p>Ingredients: Vimkunya®: 40 micrograms protein of chikungunya virus (CHIKV) virus-like particles 1,2 (VLP) adsorbed on aluminium hydroxide, hydrated</p> <p>Ixchiq®: chikungunya virus (CHIKV) Δ5nsP3 strain (live, attenuated)* not less than 3.0 log₁₀ TCID₅₀*</p>	<p>Vimkunya®: Persons ≥12 years of age:</p> <ul style="list-style-type: none"> Day 0 (1 dose) <p>Ixchiq® Persons ≥12- 59 years of age:</p> <ul style="list-style-type: none"> Day 0 (1 dose) <p>Of note:</p> <ul style="list-style-type: none"> Ixchiq® should be used only with caution in immunocompetent persons aged 12 -59 years weighing risks and benefits due to potentially serious adverse events, see NaTHNaC LINK. <p>To be documented:</p> <ul style="list-style-type: none"> Off-label use. 	<ul style="list-style-type: none"> For both vaccines: no data available on necessity or timing of booster 	<p>Vimkunya®:</p> <ul style="list-style-type: none"> No efficacy data available 12-65y: day 22: 98%; day 183: 86% ≥ 65y: day 22: 87%, day 183: 76% <p>Ixchiq®:</p> <ul style="list-style-type: none"> 2 years post vaccination: 97%, with similar results in all age groups <p>Of note: No data on immunogenicity in immunocompromised persons!</p>	<p>General considerations:</p> <ul style="list-style-type: none"> In Switzerland, chikungunya is rare among travellers, except during outbreaks. Severe disease may occur in the elderly, immunocompromised individuals, or those with serious underlying conditions. Neither Vimkunya® nor Ixchiq® is licensed in Switzerland; use in Switzerland is therefore off-label. Consultation with a travel or tropical medicine specialist is advised. <p>Indication:</p> <ol style="list-style-type: none"> Chikungunya vaccination is recommended for: <ul style="list-style-type: none"> Persons ≥12 years of age travelling to an area with a chikungunya outbreak (see current outbreaks list of US CDC). Laboratory workers who might be exposed to the virus. Chikungunya vaccination may be considered for: <ul style="list-style-type: none"> Persons ≥12 years travelling or moving to an area with elevated risk for chikungunya (see list of countries with elevated risk of US CDC) if planning to stay for an extended period of time or repeated stays (for example, cumulative period of 3 months or more). <p>Adverse events: Frequent (≥ 1/10)</p> <ul style="list-style-type: none"> Vimkunya®: injection site pain, fatigue, headache, myalgia Ixchiq®: In clinical studies, the most common solicited injection site reaction (>10%) was tenderness (10.6%). The most common solicited systemic adverse reactions (>10%) were headache (31.6%), fatigue (28.5%), myalgia (23.9%), arthralgia (17.2%), fever (13.5%) and nausea (11.2%). Chikungunya-like adverse reactions was noted in 12.1% (combinations of above adverse reactions). Of note: vaccine viremia occurs in the first week post vaccination and resolves by 14 days. <p>Contraindications:</p> <ul style="list-style-type: none"> Vimkunya®: hypersensitivity to any of the vaccine components. Ixchiq®: i) hypersensitivity to any of the vaccine components; ii) immunocompromised individuals; iii) pregnant women (though official wording in EMA is “not recommended”). <p>Immunocompromised hosts and elderly (above 60 years): Vimkunya® vaccine would be the vaccine of choice.</p> <p>Pregnancy/ Breastfeeding: Advise against travelling as also regions with frequent co-circulation of other mosquito-borne infections (e.g. zika, dengue, yellow fever, malaria etc.) and weigh risk-benefit. If vaccination is considered, Vimkunya® vaccine is recommended.</p> <p>Interactions:</p> <ul style="list-style-type: none"> Vimkunya®: Concomitant administration with other vaccines has not been studied. Ixchiq®: Concomitant administration with other vaccines has not been studied.

References:

- [1] EMA, Summary of product characteristics for [Vimkunya®](#) and [Ixchiq®](#), accessed 04.11.2025.
- [2] FDA, Package Insert [Ixchiq®](#), accessed 04.11.2025

No guarantee can be given for the accuracy and completeness of the medical information, nor can any liability be accepted for any damage that may occur.
This information cannot be forwarded without the permission of the Swiss Expert Committee for Travel Medicine (ECTM).